Clinically tested probiotics for woman health designed by SynBalance

A new scientific publication on the antimicrobial, antiadhesive and co-aggregation activity against different urogenital pathogens.

Microbiota transplant may alleviate intestinal side effects of cancer immunotherapy

The findings of a recent study suggest that FMT is an effective strategy to mitigate the intestinal side effects of cancer immunotherapy.

Gut microbiota may be linked to Alzheimer’s disease risk, clinical study finds

Understanding how gut microbes are linked to preclinical Alzheimer’s disease could help to identify markers of disease risk.

IBD, Jeroen Raes: ‘We need to treat both the patient and the gut microbiota’

Jeroen Raes, from KU Leuven, Belgium, talks about the design of clinical trials for IBD patient with microbiome based therapies.

Future prospective of FMT in IBD treatment

Lihi Godny, from Rabin Medical Center in Israel, talks about the next steps research has to focus in to improve the FMT efficacy for IBD patients.

NeurAxis Highlights Two Independent Studies Showing Benefits of IB-Stim in Adolescents Involving the Gut Microbiome

According to the authors, results suggest that patients with a specific microbial signature have a more favorable response to therapy.

Estrogen and gut microbiome-brain axis interactions in fear extinction

A recent review highlights that changes in fear-related mental health conditions are observed when the gut microbiota is altered or removed.

Engineer single strain LBPs for robust tumor microenvironment disruption

Pedro Correa de Sampaio, Chief Executive Officer at Neobe Therapeutics, talks about the challenges to remove immunosuppressive constraints that prevent the infiltration of immune cells in a subset of cancers.

New study shows Probi strain supports and improves cognitive performance

In a newly published study Probi´s proprietary strain L. plantarum HEAL9 (HEAL9™) was shown to significantly improve cognitive performance.

Developing psychobiotic LBPs tackling the gut-brain axis

Anna Chwalibóg, Chief Product Officer at Integral Solutions, talks about the opportunity to develop next-generation microbiome-based therapeutics for mental health and cognitive enhancement.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top